Boston, Massachusetts, U.S., October 8, 2026
SOPHiA GENETICS and Myriad Genetics have announced a new collaboration to advance a prostate cancer-specific genomic instability score (PrGIS) technology, with the goal of supporting precision oncology and the development of potential companion diagnostic solutions. The initiative also involves AstraZeneca and aims to advance the biomarker in clinical trials while helping expand access to precision oncology medicines. The collaboration brings together Myriad’s biomarker development expertise and SOPHiA GENETICS’ technology platform and international laboratory network. The companies are working to support approaches that may help identify patients who could benefit from targeted cancer treatments. The technology remains under development for prostate cancer, and its clinical utility and role in treatment decisions require further validation.
PrGIS Targets Genomic Instability in Prostate Cancer
Myriad Genetics developed PrGIS as a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer. HRD is an emerging prognostic and predictive biomarker in oncology, and research into its role may help inform the development of more personalized treatment strategies. The collaboration is intended to advance the technology through clinical trials and explore its use in precision oncology programs. Myriad’s MyChoice CDx test, which is already available as a companion diagnostic in ovarian cancer, is expected to generate the PrGIS score as the technology is advanced toward a potential new indication in prostate cancer. A companion diagnostic can help identify patients whose disease characteristics may make them suitable for a particular therapy.
However, the planned prostate cancer application should not be confused with an already approved or established use: further clinical evaluation and validation are needed to determine how PrGIS may support patient selection in this setting. The companies are positioning the collaboration around the development of biomarker-driven approaches that could support clinical research and future companion diagnostic strategies. The work is intended to help biopharmaceutical partners investigate patient subgroups and evaluate precision medicine approaches in prostate cancer.
SOPHiA GENETICS Develops a Decentralized Diagnostic Approach
Advertisement
As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The planned approach will incorporate Myriad’s PrGIS technology and is intended to broaden access to testing across international markets. SOPHiA GENETICS operates a cloud-based, technology-agnostic platform that analyzes genomic and other complex health data. According to the company, its global network includes more than 1,000 connected institutions across over 75 countries. The network could provide a foundation for local laboratory testing and support the wider deployment of biomarker-based diagnostic approaches.
Decentralized testing may help bring diagnostic capabilities closer to patients and healthcare providers, rather than relying exclusively on centralized testing facilities. In precision oncology, access to timely and appropriate molecular testing can be important when treatment decisions depend on specific biological characteristics of a tumor. The proposed solution aims to connect biomarker technology with a broad laboratory network, although its eventual availability and clinical role will depend on development, validation and applicable regulatory requirements.
ESMO Research Expected to Further Characterize PrGIS
Myriad also plans to present research on PrGIS at the 2026 European Society for Medical Oncology (ESMO) Congress. The research is co-authored with AstraZeneca and is expected to further characterize the biomarker and contribute to its validation. The companies stated that the full data would be available after the congress embargo period. The research could provide additional information about how PrGIS is being evaluated in prostate cancer and how the biomarker may fit into clinical development programs. Its significance will depend on the study findings and the evidence generated through further validation. For the oncology field, the collaboration reflects ongoing efforts to combine molecular biomarker development, computational platforms and diagnostic networks to support personalized cancer care. The immediate focus is on advancing PrGIS through clinical research and developing a potential companion diagnostic approach. The collaboration does not establish that PrGIS is already validated for routine prostate cancer treatment selection, but it represents a development effort aimed at expanding biomarker-based precision oncology.
Source: SOPHiA GENETICS, Myriad Genetics press release
